New combo aims to stall breast cancer spread
NCT ID NCT01560416
First seen Mar 21, 2026 · Last updated Jun 13, 2026 · Updated 15 times
Summary
This study tested whether adding ganetespib, an experimental drug that blocks cancer cell growth, to the standard hormone therapy fulvestrant could better control metastatic breast cancer. Fifty adults with hormone receptor-positive, HER2-negative breast cancer that had spread and become resistant to hormone therapy took part. The main goal was to see if the combination delayed cancer progression compared to fulvestrant alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
DFCI at Faulkner Hospital
Boston, Massachusetts, 02130, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
New Hampshire Oncology and Hematology, P.A.
Concord, New Hampshire, 03301, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.